[ad_1]
The Spanish Agency for Medicines and Health Products (AEMPS) has reported that the restoration of the supply of ‘Tenormin‘ (atenolol) 0.5 mg/ml solution for injection, 5 ampoules of 10 ml. (CN 966317) is delayed to mid-July, as reported Atnahs Pharma Netherlands.
The AEMPS, attached to the Ministry of Healthwarned last November that the supply of ‘Tenormin’, indicated for the treatment of cardiac arrhythmias and for early intervention in the acute phase of acute myocardial infarction, it would be reinstated in February and, in that month, it was announced that it would be postponed to mid-April.
In a new statement, it has indicated that the forecast is delayed to July and, given the high impact of the lack of the medicine in the market, it has indicated that it is managing the importation of foreign medication, with the aim of guaranteeing access to treatment for patients during the situation of lack. However, he has indicated that, to date, no units have been found.
As a mitigating measure, the Agency has recommended that healthcare professionals refer patients to possible therapeutic alternatives available on the national market that, depending on the clinical situation, may be considered appropriate, such as other intravenous beta-blockers or other intravenous antiarrhythmic medications belonging to other therapeutic groups.
[ad_2]
Source link
